SIL index, comprising stage, soluble interleukin‐2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B‐cell lymphoma

Rituximab (R) plus doxorubicin, cyclophosphamide, vincristine, and prednisolone (CHOP) chemotherapy (R‐CHOP) is widely accepted as standard care for diffuse large B‐cell lymphoma (DLBCL) patients. The revised International Prognostic Index (R‐IPI) was established in 2007 after the addition of rituxi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Sci
Päätekijät: Tomita, Naoto, Sakai, Rika, Fujisawa, Shin, Fujimaki, Katsumichi, Taguchi, Jun, Hashimoto, Chizuko, Ogawa, Koji, Yamazaki, Etsuko, Ishigatsubo, Yoshiaki
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2012
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7659199/
https://ncbi.nlm.nih.gov/pubmed/22587388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02331.x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia